Nita Jain is the founder and CEO of Timeless Biosciences, where she leads scientific strategy and pipeline development for TB-001, the company's lead program targeting F. nucleatum-induced chemoresistance in colorectal cancer, with chemo-induced GI toxicity as a secondary indication.
Her research background spans microbiome science, systems biology, and complex chronic illness, with a focus on the mechanisms by which microbial metabolites regulate mucosal immunity, barrier integrity, and xenobiotic metabolism.
She holds clinical trial advisory roles on the NIH RECOVER Initiative and Emory's REVERSE-LC study, and she is a 2025 NIA Start-Up Challenge Finalist. Her approach to drug development is mechanistically rigorous and systems-informed, examining how spatiotemporal and environmental factors shape molecular and metabolic disease pathology.
